A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT05658601
Drugs and interventions used in this trial
0 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No interventions are currently published for this study in CureCurrent. View the original registry record below.
Study at a glance
Registry-backedA Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified
Read study objectives, eligibility and outcome measures at ClinicalTrials.govConditions
Interventions
Sponsors & collaborators
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05658601 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.